A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
Public ClinicalTrials.gov record NCT05296798. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Giredestrant in Combination With Phesgo Versus Phesgo After Induction Therapy With Phesgo + Taxane in Patients With Previously Untreated HER2-Positive, Estrogen Receptor-Positive Locally-Advanced or Metastatic Breast Cancer
Study identification
- NCT ID
- NCT05296798
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Enrollment
- 922 participants
Conditions and interventions
Conditions
Interventions
- Docetaxel Drug
- Giredestrant Drug
- LHRH Agonist Drug
- Optional Endocrine Therapy of Investigator's Choice Drug
- Paclitaxel Drug
- Phesgo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 17, 2022
- Primary completion
- Oct 30, 2027
- Completion
- Dec 30, 2030
- Last update posted
- Apr 15, 2026
2022 – 2030
United States locations
- U.S. sites
- 16
- U.S. states
- 9
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Clinical Research Center, Inc | Tucson | Arizona | 85715 | — |
| Los Angeles Hematology Oncology Medical Group | Los Angeles | California | 90017 | — |
| Cancer Specialists of North Florida | Jacksonville | Florida | 32256 | — |
| Maryland Oncology Hematology - Annapolis | Annapolis | Maryland | 21401 | — |
| St. Joseph Mercy Hospital | Ann Arbor | Michigan | 48106 | — |
| Henry Ford Hospital | Detroit | Michigan | 48202 | — |
| St. Joseph Mercy Oakland | Pontiac | Michigan | 48341 | — |
| Queens Hospital Cancer Center | Jamaica | New York | 11432 | — |
| Clinical Research Alliance | Westbury | New York | 11590 | — |
| West Cancer Center | Germantown | Tennessee | 38138 | — |
| CHRISTUS Spohn Cancer Center - Shoreline | Corpus Christi | Texas | 78404 | — |
| Texas Oncology - DFW | Dallas | Texas | 75246 | — |
| Texas Oncology - El Paso | El Paso | Texas | 79902 | — |
| Swedish Cancer Institute - Edmonds Campus | Edmonds | Washington | 98026 | — |
| Swedish Cancer Institute - Issaquah | Issaquah | Washington | 98029 | — |
| Swedish Cancer Institute | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 190 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05296798, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 15, 2026 · Synced Apr 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05296798 live on ClinicalTrials.gov.